Literature DB >> 20027518

[Evaluating the burden of disease caused by human papillomavirus in Bogota].

Fernando de la Hoz-Restrepo1, Nelson Alvis-Guzmán, Javier Narváez, Luz A Chocontá-Piraquive.   

Abstract

OBJECTIVE: A study was carried out in Bogota aimed at estimating the burden of disease associated with human papillomavirus infection (HPV) and the potentially avoidable percentage due to using new vaccines.
METHODS: A literature review was combined with analysing surveillance system data and disease cost evaluation.
RESULTS: After adjusting for underreporting and misclassification, it was estimated that 322 deaths from cervical cancer occur annually in Bogota (corresponding to 676 new cases). This would cause the loss of 15 years of life for each 1,000 women per year (most occurring amongst women aged 40 to 69). In addition to cervical cancer, there would be around 6,084 cases of high-grade and 22,984 low-grade cervical lesions yearly. The disease's yearly cost would amount to around 7 million dollars. Important weaknesses were found in the clinical management of women suffering from cervical lesions.
CONCLUSION: Strengthening cervical cancer prevention programmes in Bogota would lead to saving a significant number of deaths, cases of cancer and the costs associated with HPV infection. Introducing an anti-HPV vaccine may be considered, but only as part of a more widespread preventative strategy and provided that more affordable prices have been found.

Entities:  

Mesh:

Year:  2009        PMID: 20027518     DOI: 10.1590/s0124-00642009000300014

Source DB:  PubMed          Journal:  Rev Salud Publica (Bogota)        ISSN: 0124-0064


  2 in total

1.  Cancer risk associated with living at high altitude in Ecuadorian population from 2005 to 2014.

Authors:  David Israel Garrido; Santiago Moises Garrido
Journal:  Clujul Med       Date:  2018-04-25

2.  Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia.

Authors:  Johanna Aponte-González; Luisa Fajardo-Bernal; Jorge Diaz; Javier Eslava-Schmalbach; Oscar Gamboa; Joel W Hay
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.